Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection With Interferon or Direct Antiviral Therapy.

Autor: Tsai YN; Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.; School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan., Lo JC; School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan., Tseng CH; Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.; School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan., Hsieh SC; Division of Allergy, Immunology, and Rheumatology, National Taiwan University Hospital, Taipei, Taiwan., Chiu WC; School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan., Tai CM; School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.; Division of Gastroenterology and Hepatology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan., Chang CY; Division of Gastroenterology, Fu-Jen Catholic University Hospital, New Taipei, Taiwan.; School of Medicine, Fu Jen Catholic University, New Taipei, Taiwan., Lee FJ; Division of Gastroenterology, Fu-Jen Catholic University Hospital, New Taipei, Taiwan.; School of Medicine, Fu Jen Catholic University, New Taipei, Taiwan., Nguyen MH; Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.; Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, California, USA., Lin JT; Division of Gastroenterology and Hepatology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan., Hsu YC; School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.; Division of Gastroenterology and Hepatology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Jazyk: angličtina
Zdroj: Journal of viral hepatitis [J Viral Hepat] 2025 Jan; Vol. 32 (1), pp. 1-8.
DOI: 10.1111/jvh.14047
Abstrakt: Hepatitis C virus (HCV) infection is associated with a myriad of extrahepatic manifestations (EHM), as well as the production of autoantibodies, including rheumatoid factor (RF). This study aims to elucidate whether serum levels of RF change before and after HCV eradication, and whether these changes differ according to the type of therapy used. This is a retrospective cohort study of adults with chronic HCV infection treated with interferon-free or interferon-based regimens. All patients had HCV viremia at baseline and documented sustained virological response (SVR) 12 or 24 weeks after completing treatment. We measured the serum levels of RF at baseline and at SVR-12 or -24 to analyse the changes after eradication. This study enrolled 297 patients (median age, 59 years; female, 48.5%; cirrhosis, 16.8%). Among them, 78 (26.3%) were RF-positive by qualitative serology at baseline. This number decreased to 49 (16.5%) at SVR-12 or -24 (p < 0.001). Quantitatively, the median RF also decreased from 1.6 IU/mL (interquartile range [IQR], undetectable-15.8) to undetectable (IQR, undetectable-6.6 IU/mL) (p < 0.001). Significant reductions were observed in both groups. The proportion with RF seropositivity decreased from 24.3% to 15.4% (p = 0.001) in patients treated with interferon-free agents (n = 214) and from 31.3% to 19.3% (p = 0.006) in patients treated with interferon-based regimens (n = 83), without significant difference between two groups (p = 0.40). Serum RF decreased after HCV eradication, regardless of treatment regimen. Our findings suggest that HCV eradication may attenuate HCV-related autoimmunity.
(© 2024 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: